EUVIMEDEUVIMED entdecken
EditorialKommentarRandomisierte kontrollierte Studie

Retrospective aprotinin cardiac surgical studies and their limitations: time for a prospective randomized clinical trial

Gabor Erdoes iD, Andreas Koster, Jerrold H Levy

European Journal of Cardio-Thoracic Surgery · 2024

DOI: 10.1093/ejcts/ezae038 ↗

Kurz gefasst

Editorial in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2024. Verfasst von Gabor Erdoes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Tranexamic Acid, Hemostatics, Cardiac Surgical Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aprotinin is a unique pharmacologic agent that inhibits fibrinolysis, contact activation and protease-activated receptors that has been extensively studied in cardiac surgery patients [1]. Randomized clinical trials (RCTs) investigating this drug have consistently shown a reduction in postoperative blood loss, allogeneic blood product transfusion and anti-inflammatory effects compared to placebo. In this context, it is plausible that following the suspension of aprotinin's marketing authorization by the European Medicines Agency in 2008, efforts have been made to re-evaluate the efficacy and safety of this potent, broad-spectrum protease inhibitor. In the current issue of the European Journal of Cardiothoracic Surgery, Gallo et al. present their results from a retrospective database comparing a half-dose aprotinin protocol with a tranexamic acid regimen in cardiac surgery patients [2]. The authors found no differences in major bleeding or blood products transfused between the treatment groups, but a twofold increased hazard ratio for thromboembolic events in patients receiving aprotinin. This report raises a number of important considerations. As a reminder, although aprotinin was removed from the market, following an independent review of the study results that led to aprotinin suspension and a positive benefit-risk ratio based on a re-analysis involving prophylactic use, aprotinin was reinstated in the European market in 2016 for patients at high risk of major blood loss undergoing isolated coronary artery bypass grafting (CABG) [3] due to factors contributing to increased bleeding risk including dual antiplatelet therapy, direct oral anticoagulants use or thrombocytopaenia. Unfortunately, neither a homogeneous patient population nor a uniform aprotinin dosing regimen could be agreed upon for the Nordic Aprotinin Patient Registry (NAPaR) [4], which was established primarily to examine aprotinin use in Europe and monitor potential side effects. Similarly, the report by Gallo included a wide variety of cardiac surgeries (heart transplantation, left ventricular assist device implantation, aortic arch surgery) and only 10% of the patients were isolated CABG. In high-risk cardiac surgery, the underlying increased risk for adverse outcomes, morbidity and mortality prevents distinguishing between patient- or procedural-associated and drug-related morbidity. Therefore, a well-selected, homogeneous patient and procedure cohort is a prerequisite for meaningful conclusions regarding drug efficacy, safety and side effects. In the report by Gallo, tranexamic acid dosing was heterogeneous and thus inconsistent between centres, ranging from low to high dose protocols (10–30 mg kg−1), and the incidence of seizures—an important, dose-dependent adverse effect of tranexamic acid [5]—was not or could not be evaluated, the latter being a typical shortcoming of retrospective analyses. A similar pattern of heterogeneous antifibrinolytic therapy was applied in another before-and-after trial analysing pooled data [6]. This evaluation claimed to have examined safety outcomes in isolated CABG patients treated with aprotinin or tranexamic acid, but, again, no seizures were reported. Gallo and colleagues state that aprotinin was associated with an increased risk of thromboembolic events. The differences in postoperative thromboembolic complications were numerically relatively small, and although they add up, these retrospective observational data analyses are always subject to potential limitations that are not apparent from the analysis. This association is noteworthy given that aprotinin and its potent broad-spectrum protease inhibition also attenuate intrinsic coagulation system and platelet activation. However, in cases where thromboembolism occurs, and the causes are discussed, the intraoperative anticoagulation protocol and the postoperative thromboprophylaxis need to be evaluated. In the context of an RCT, the ‘site randomization’ strategy might have compensated for such an obvious bias. However, in the context of a retrospective study design, differences in postoperative anticoagulation protocols may outweigh the effects of intraoperative anticoagulation strategies. In this regard, we believe the results presented in Gallo's report regarding thromboembolic events should be cautiously interpreted. Based on the available data, we do not believe that significant new information on the efficacy-safety profile of aprotinin has been gained in recent years. Observational studies and registry data are important to identify potential safety concerns when using potent drugs in specific indications and for more homogeneous populations. Nevertheless, we believe that reliable data on the efficacy and especially the safety of potent drugs such as aprotinin can only be obtained in the context of appropriate RCTs. In such studies, the selection of procedures and patients is paramount to reduce the contribution and confounding effects of surgical procedure and patient-related morbidity and generate clear data sets. Therefore, we believe that a homogeneous patient population undergoing less complex procedures is better suited to study drug-related morbidity. In addition, the recent meta-analysis on the dose–response relationship of tranexamic acid supports the use of a low-dose protocol to balance efficacy and seizure risk [7]. With this in mind, we would welcome a low-dose tranexamic acid protocol to serve as a competitor to a half-dose aprotinin protocol, and we consider seizure assessment an essential component of the morbidity data. Although we believe that aprotinin has a place in high bleeding-risk cardiac surgery (and not exclusively in isolated CABG), neither aprotinin nor tranexamic acid has been adequately studied in a comparative prospective RCT. This is critical to evaluating comparative drug safety data, particularly in high-risk transfusion surgery or disease states where the underlying disease strongly influences outcomes. With this in mind, we consider the time is ripe to continue these efforts in the context of adequately powered RCTs. Enough low evidence is enough.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidHemostaticsCardiac Surgical ProceduresHumansAprotininProspective StudiesAPACHERetrospective Studies

Stichwörter der Autor:innen

Aprotinincardiac surgerycardiopulmonary bypassfibrinolysisrandomized controlled trial

Substanzen

AprotininTranexamic AcidHemostatics

Autor:innen und Institutionen

  • Department of Anesthesiology and Pain Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Clinics of Anesthesiology and Intensive Care Medicine, Sana Heart Center Cottbus, Cottbus, Germany.
  • Institute of Anesthesiology and Pain Therapy, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.
  • Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.

ORCID-Profile: Gabor Erdoes

Zitieren

APA

Erdoes, G., Koster, A., & Levy, J. H. (2024). Retrospective aprotinin cardiac surgical studies and their limitations: time for a prospective randomized clinical trial. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezae038

Vancouver

Erdoes G, Koster A, Levy JH. Retrospective aprotinin cardiac surgical studies and their limitations: time for a prospective randomized clinical trial. European Journal of Cardio-Thoracic Surgery. 2024. doi:10.1093/ejcts/ezae038

BibTeX
@article{Erdoes2024,
  author = {Erdoes, Gabor and Koster, Andreas and Levy, Jerrold H},
  title = {Retrospective aprotinin cardiac surgical studies and their limitations: time for a prospective randomized clinical trial},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2024},
  doi = {10.1093/ejcts/ezae038}
}
Kostenlos starten →